1. Home
  2. ATYR vs CXDO Comparison

ATYR vs CXDO Comparison

Compare ATYR & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • CXDO
  • Stock Information
  • Founded
  • ATYR 2005
  • CXDO 1995
  • Country
  • ATYR United States
  • CXDO United States
  • Employees
  • ATYR N/A
  • CXDO N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • CXDO Telecommunications Equipment
  • Sector
  • ATYR Health Care
  • CXDO Telecommunications
  • Exchange
  • ATYR Nasdaq
  • CXDO Nasdaq
  • Market Cap
  • ATYR 126.3M
  • CXDO 121.3M
  • IPO Year
  • ATYR 2015
  • CXDO 1998
  • Fundamental
  • Price
  • ATYR $2.23
  • CXDO $5.19
  • Analyst Decision
  • ATYR Strong Buy
  • CXDO Strong Buy
  • Analyst Count
  • ATYR 4
  • CXDO 2
  • Target Price
  • ATYR $19.25
  • CXDO $6.50
  • AVG Volume (30 Days)
  • ATYR 586.5K
  • CXDO 85.5K
  • Earning Date
  • ATYR 11-07-2024
  • CXDO 11-07-2024
  • Dividend Yield
  • ATYR N/A
  • CXDO N/A
  • EPS Growth
  • ATYR N/A
  • CXDO N/A
  • EPS
  • ATYR N/A
  • CXDO 0.10
  • Revenue
  • ATYR $588,000.00
  • CXDO $57,009,000.00
  • Revenue This Year
  • ATYR N/A
  • CXDO $14.41
  • Revenue Next Year
  • ATYR $2,057.88
  • CXDO $12.53
  • P/E Ratio
  • ATYR N/A
  • CXDO $53.61
  • Revenue Growth
  • ATYR N/A
  • CXDO 24.72
  • 52 Week Low
  • ATYR $1.08
  • CXDO $1.54
  • 52 Week High
  • ATYR $2.50
  • CXDO $7.59
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 74.37
  • CXDO 61.55
  • Support Level
  • ATYR $1.83
  • CXDO $4.80
  • Resistance Level
  • ATYR $1.96
  • CXDO $5.24
  • Average True Range (ATR)
  • ATYR 0.09
  • CXDO 0.29
  • MACD
  • ATYR 0.05
  • CXDO 0.07
  • Stochastic Oscillator
  • ATYR 93.33
  • CXDO 89.19

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About CXDO Crexendo Inc.

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of revenue from the Cloud telecommunications segment.

Share on Social Networks: